glp-1 obesity drug news today october 23 2025 How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 A North Carolina woman was

Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes

A 2025 real-world safety comparison found the two drugs had distinct safety profiles, rather than one being safer overall

In STEP-1 (semaglutide), lean mass decreased by ~9.7% while fat mass fell by ~19.3%, with the proportion of lean mass increasing by ~3 percentage points ( Limited preclinical and clinical data, particularly from MRI-based studies, suggest that skeletal muscle changes induced by GLP-1RAs may be adaptive

You may give other people a serious infection or get a serious infection from them

Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial